- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05297695
Helicobacter Pylori Eradication Therapy for Epileptic Children
Effect of Treating Helicobacter Pylori Infection on Seizure Frequency in Children With Drug-Resistant Idiopathic Generalized Epilepsy
Study Overview
Status
Intervention / Treatment
Detailed Description
Helicobacter pylori (H. pylori) is a spiral-shaped Gram-negative bacterium, which causes chronic infection in more than 50% of human population. H. pylori infection is associated with several gastrointestinal disorders, such as gastritis and gastric/duodenal ulcers. Moreover, accumulating body of evidence indicates the possible role of H. Pylori infection in extraintestinal health problems, such as iron deficiency anemia, immune thrombocytopenic purpura (ITP), numerous dermatological diseases, Alzheimer disease, Parkinson's disease, multiple sclerosis, and epilepsy.
Epilepsy is a common neurological disorder characterized by recurrent unprovoked seizures. This condition affects 0.5% to 1% of all children and is associated with neurobiological, cognitive, psychological, and social consequences. Seizures can usually be controlled by anti-epileptic drugs (AEDs) in up to two-thirds of children with epilepsy. However, this leaves a significant part of epileptic children whose seizures are not controlled by pharmacotherapy.
The development of epilepsy is highly complex and can be attributed to multiple etiologies classified into structural (e.g., malformation, trauma, ischemia), genetic, infectious, metabolic, and immune factors. However, the etiology remains unknown in about half of epileptic children. Idiopathic generalized epilepsies (IGE) constitute about one-third of all epilepsies. Efforts to explore new possible mechanisms contributing to the development of epilepsy, particularly drug-resistant IGE, could contribute to the development of new therapeutic strategies to improve patients' outcomes.
The role of H. pylori infection in epilepsy has been investigated in a few studies, some of which reported that the seroprevalence of H. pylori infection is significantly higher in patients with idiopathic epilepsy compared with patients with other chronic diseases, and that H. pylori infection is associated with poor prognosis.
Potential H. pylori-induced epileptic effects are probably immune-mediated that can be attributed to a cross-mimicry mechanism between H. pylori and human cellular phospholipids with production of autoimmune antibodies (e.g., anti-cardiolipin) and H. pylori infection-related activation of pro-inflammatory cells with systemic release of proinflammatory cytokines (e.g., IL-6, 8 and TNF- α) which are involved in disruption of the blood-brain barrier and neuroinflammation.
To the best of our knowledge, there have been no previous studies on the effect of treating H. pylori infection on seizure frequency among children with drug-resistant IGE. This study aims to evaluate the effect of treating H. pylori infection on seizure frequency among children with drug-resistant IGE.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Mina s Basily, MD
- Phone Number: 01200049910
- Email: menasamy@med.sohag.edu.eg
Study Contact Backup
- Name: Elsayed Abdelkreem, MD, PhD
- Phone Number: 01114232126
- Email: d.elsayedmohammed@med.sohag.edu.eg
Study Locations
-
-
-
Sohag, Egypt, 82524
- Sohag university Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age between 4 and 18 years.
- Idiopathic generalized epilepsies (IGE), including childhood absence epilepsy, juvenile absence epilepsy, juvenile myoclonic epilepsy, or IGE with generalized tonic-clonic seizures only (IGE-TCS).
- Drug-resistant epilepsy, defined as failure of adequate trials of two tolerated and appropriately chosen and used anti-epileptic drugs schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom
- Positive H. pylori stool antigen (HpSA) test (at initial screening).
Exclusion Criteria:
- Failure to obtain informed consent.
- Presence of a medical indication for treating H. pylori infection, including gastric or duodenal ulcer, chronic immune thrombocytopenic purpura, and refractory iron deficiency anemia.
- Known allergy or contraindications to any of the study drugs.
- Treatment with antibiotics and/or proton pump inhibitors in the last 2 months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Study group
Children with drug-resistant idiopathic generalized epilepsy and positive H. pylori stool antigen test who will receive H. pylori eradication therapy.
|
Triple therapy for H. pylori infection (Esomeprazole, Amoxicillin, and Clarithromycin) for two weeks
|
No Intervention: Control group
Children with drug-resistant idiopathic generalized epilepsy and positive H. pylori stool antigen test who will not receive H. pylori eradication therapy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Seizure improvement
Time Frame: 2.5 months following H. pylori eradication therapy
|
≥ 50% seizure frequency reduction compared with baseline
|
2.5 months following H. pylori eradication therapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Need for escalation of antiepileptic drugs
Time Frame: 2.5 months following H. pylori eradication therapy
|
Need for escalation of antiepileptic drugs compared with baseline
|
2.5 months following H. pylori eradication therapy
|
Occurrence of adverse effects of H. pylori eradication therapy
Time Frame: 2.5 months following H. pylori eradication therapy
|
2.5 months following H. pylori eradication therapy
|
|
Occurrence of status epilepticus
Time Frame: 2.5 months following H. pylori eradication therapy
|
2.5 months following H. pylori eradication therapy
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Montaser M Mohamed, MD, PhD, Sohag University
Publications and helpful links
General Publications
- Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, Engel J Jr, Forsgren L, French JA, Glynn M, Hesdorffer DC, Lee BI, Mathern GW, Moshe SL, Perucca E, Scheffer IE, Tomson T, Watanabe M, Wiebe S. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014 Apr;55(4):475-82. doi: 10.1111/epi.12550. Epub 2014 Apr 14.
- Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, Moshe SL, Perucca E, Wiebe S, French J. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010 Jun;51(6):1069-77. doi: 10.1111/j.1528-1167.2009.02397.x. Epub 2009 Nov 3. Erratum In: Epilepsia. 2010 Sep;51(9):1922.
- Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, Hirsch E, Jain S, Mathern GW, Moshe SL, Nordli DR, Perucca E, Tomson T, Wiebe S, Zhang YH, Zuberi SM. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017 Apr;58(4):512-521. doi: 10.1111/epi.13709. Epub 2017 Mar 8.
- Korotkaya Y, Shores D. Helicobacter pylori in Pediatric Patients. Pediatr Rev. 2020 Nov;41(11):585-592. doi: 10.1542/pir.2019-0048.
- Fine A, Wirrell EC. Seizures in Children. Pediatr Rev. 2020 Jul;41(7):321-347. doi: 10.1542/pir.2019-0134.
- Yao G, Wang P, Luo XD, Yu TM, Harris RA, Zhang XM. Meta-analysis of association between Helicobacter pylori infection and multiple sclerosis. Neurosci Lett. 2016 May 4;620:1-7. doi: 10.1016/j.neulet.2016.03.037. Epub 2016 Mar 23.
- Okuda M, Miyashiro E, Nakazawa T, Minami K, Koike M. Helicobacter pylori infection and idiopathic epilepsy. Am J Med. 2004 Feb 1;116(3):209-10. doi: 10.1016/j.amjmed.2003.05.005. No abstract available.
- Ozturk A, Ozturk CE, Ozdemirli B, Yucel M, Bahcebasi T. Helicobacter pylori infection in epileptic patients. Seizure. 2007 Mar;16(2):147-52. doi: 10.1016/j.seizure.2006.10.015. Epub 2006 Nov 27.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- soh-med-22-03-13
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epilepsy, Generalized
-
NYU Langone HealthRecruiting
-
Institut National de la Santé Et de la Recherche...CompletedIdiopathic Generalized EpilepsyFrance
-
University Hospital, LilleRecruitingIdiopathic Generalized EpilepsyFrance
-
NeuroPaceActive, not recruitingEpilepsy | Idiopathic Generalized Epilepsy | Generalized Tonic Clonic SeizureUnited States
-
University of AlexandriaCompletedEpilepsy Generalized Idiopathic Not Intractable
-
SK Life Science, Inc.RecruitingPrimary Generalized EpilepsyUnited States, Spain, Germany, Hungary, Korea, Republic of, Australia, Bulgaria, Czechia, Poland, Slovakia, Ukraine
-
UCB PharmaCompleted
-
Oslo University HospitalCompletedEpilepsy | Generalized Epilepsy | Focal EpilepsyNorway
-
SK Life Science, Inc.Enrolling by invitationPrimary Generalized Tonic Clonic Seizures in the Setting of Idiopathic Generalized EpilepsyUnited States, Bulgaria, Czechia, Hungary, Poland, Slovakia, Ukraine
-
Assiut UniversityNot yet recruitingPsychiatric Comorbidities
Clinical Trials on Triple therapy for H. pylori infection
-
Federal University of São PauloFundação de Amparo à Pesquisa do Estado de São PauloCompletedHelicobacter Pylori Infection | Immune Thrombocytopenic PurpuraBrazil
-
University of AlbertaCanadian Institutes of Health Research (CIHR); Alberta Innovates Health Solutions and other collaboratorsCompleted
-
Fudan UniversityRecruitingHelicobacter Pylori Infection | MALT Lymphoma of StomachChina
-
George Washington UniversityCompletedGastritis | Peptic Ulcer | Stomach Ulcer | Peptic Ulcer PerforationUnited States
-
Ziauddin UniversityCompletedHelicobacter Pylori InfectionPakistan
-
University of Erlangen-Nürnberg Medical SchoolCompletedH. Pylori InfectionGermany
-
National University of MalaysiaCompletedResponse to Levodopa | Motor Outcomes | Quality of Life OutcomesMalaysia
-
Hamamatsu UniversityUnknownH. Pylori InfectionJapan
-
Hospital Authority, Hong KongThe University of Hong KongUnknown
-
Sohag UniversityRecruitingHelicobacter Pylori Infection in Patients With Chronic TonsillitsEgypt